Advertisement

International Urogynecology Journal

, Volume 27, Issue 5, pp 723–733 | Cite as

Incontinence medication response relates to the female urinary microbiota

  • Krystal J. Thomas-White
  • Evann E. Hilt
  • Cynthia Fok
  • Meghan M. Pearce
  • Elizabeth R. Mueller
  • Stephanie Kliethermes
  • Kristin Jacobs
  • Michael J. Zilliox
  • Cynthia Brincat
  • Travis K. Price
  • Gina Kuffel
  • Paul Schreckenberger
  • Xiaowu Gai
  • Linda Brubaker
  • Alan J. Wolfe
Original Article

Abstract

Introduction and hypothesis

Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. We hypothesized that microbiome/microbiota characteristics would relate to clinically relevant treatment response to UUI medication per os.

Methods

Adult women initiating medication treatment orally for UUI and a comparator group of unaffected women were recruited in a tertiary care health-care system. All participants provided baseline clinical data and urine samples. Women with UUI were given 5 mg solifenacin, with potential dose escalation to 10 mg for inadequate UUI symptom control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed using 16S ribosomal RNA (rRNA) gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC.

Results

Diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Nonresponders had a more diverse community that often included bacteria not typically found in responders.

Conclusions

Knowledge of an individual’s urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing, and expanded urine culture provide information about bacteria that appear to be related to UUI incontinence status and treatment response in this population of adult women.

Keywords

Urinary incontinence Clinical microbiology Solifenacin 

Notes

Acknowledgments

We kindly thank Mary Tulke RN and Bozena Zemaitaitis for their assistance with participant recruitment and sample collection and Kathleen McKinley MT (ASCP) for her clinical microbiology contributions. We acknowledge and thank the Loyola University Chicago Health Sciences Division’s Office of Informatics and Systems Development for their expertise and for computational resources used in support of this research.

Funding/Support

This study was supported by a grant from the Falk Foundation (LU#202567), by NIH grant R21DK097435-01A1, and by Astellas Scientific and Medical Affairs (ASMA) (Wolfe PI) and is registered at www.clinicaltrials.gov as NCT01642277. Loyola University Chicago Stritch School of Medicine’s research computing facility was developed through grant funds awarded by the Department of Health and Human Services as award number 1G20RR030939-01. The following reagent was obtained through BEI Resources, NIAID, NIH as part of the Human Microbiome Project: Genomic DNA from Microbial Mock Community A (Even, Low Concentration), HM-782D. Our funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. ASMA was given a courtesy review.

Conflicts of interest

All Authors have completed and submitted ICMJE Form for Disclosure of Potential Conflicts of Interest.

All authors report that this study was funded in part by a grant from Astellas Scientific and Medical Affairs (ASMA).

Alan J. WOLFE, Ph.D. – Scientific Study/Trial: Investigator Initiated Grant from ASMA for certain aspects of this study.

Linda BRUBAKER, MD – Scientific Study/Trial: Grants from NICHD and NIDDK during conduct of a different study. Health Publishing: Personal fees from Up-To-Date.

Elizabeth R. MUELLER, M.D. reports grants from ASMA, during the conduct of the study; grants and personal fees from ASMA, personal fees from Peri-Coach, and personal fees from Allergan, outside the submitted work.

Reprints will not be available.

Supplementary material

192_2015_2847_MOESM1_ESM.docx (159 kb)
ESM 1 (DOCX 159 kb)

References

  1. 1.
    Hartmann KE, McPheeters ML, Biller DH, Ward RM, McKoy JN, Jerome RN, Micucci SR, Meints L, Fisher JA, Scott TA, Slaughter JC, Blume JD (2009) Treatment of overactive bladder in women. Evid Rep/Technol Assess 187:1–120Google Scholar
  2. 2.
    Hoffstetter S, Leong FC (2009) Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metab Toxicol 5(3):345–350CrossRefPubMedGoogle Scholar
  3. 3.
    Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group (2005) Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47(3):376–384CrossRefPubMedGoogle Scholar
  4. 4.
    Pelman RS, Capo JP Jr, Forero-Schwanhaeuser S (2008) Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med 120(2):85–91CrossRefPubMedGoogle Scholar
  5. 5.
    Santos JC, Telo ER (2010) Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol 63(3):197–213PubMedGoogle Scholar
  6. 6.
    Whiteside SA, Razvi H, Dave S, Reid G, Burton JP (2015) The microbiome of the urinary tract - a role beyond infection. Nat Rev Urol 12(2):81–90CrossRefPubMedGoogle Scholar
  7. 7.
    Brubaker L, Wolfe AJ (2015) The new world of the urinary microbiota in women. Am J Obstet Gynecol. doi: 10.1016/j.ajog.2015.05.032 (Epub ahead of print Google Scholar
  8. 8.
    Wolfe AJ, Brubaker L (2015) “Sterile Urine” and the Presence of Bacteria. Eur Urol 68(2):173–174CrossRefPubMedGoogle Scholar
  9. 9.
    Brubaker L, Nager CW, Richter HE, Visco A, Nygaard I, Barber MD, Schaffer J, Meikle S, Wallace D, Shibata N, Wolfe AJ (2014) Urinary bacteria in adult women with urgency urinary incontinence. Int Urogynecol J 25(9):1179–84CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, Brubaker L, Gai X, Wolfe AJ, Schreckenberger PC (2014) Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol 52(3):871–876CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger P, Brubaker L, Gai X, Wolfe AJ (2014) The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 5(4):e01283–14CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M, Mueller ER, Schreckenberger P, Dong Q, Nelson DE, Brubaker L (2012) Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol 50(4):1376–1383CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, Huang ST, Ljungberg I, Sprague BM, Lucas SK, Torralba M, Nelson KE, Groah SL (2012) Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 10:174CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS (2011) Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol 11:244CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Khasriya R, Sathiananthamoorthy S, Ismail S, Kelsey M, Wilson M, Rohn JL, Malone-Lee J (2013) Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. J Clin Microbiol 51(7):2054–2062CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, Drake MJ (2013) The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infec Microbiol 3:41CrossRefGoogle Scholar
  17. 17.
    Barber MD, Walters MD, Cundiff GW (2006) Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment for pelvic organ prolapse. Am J Obstet Gynecol 194(5):1492–1498CrossRefPubMedGoogle Scholar
  18. 18.
    Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139CrossRefPubMedGoogle Scholar
  19. 19.
    Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res : Int J Qual Life Asp Treat, Care Rehabil 11(6):563–574CrossRefGoogle Scholar
  20. 20.
    Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J, Pelvic Floor Disorders N (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180(1):217–222CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75(23):7537–7541CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Team RDC (2014) R: a language and environment for statistical computing. R Foundation for Statistical ComputingGoogle Scholar
  23. 23.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174CrossRefPubMedGoogle Scholar
  24. 24.
    Hooton TM, Roberts PL, Cox ME, Stapleton AE (2013) Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 369(20):1883–1891CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Maskell RM (2010) The natural history of urinary tract infection in women. Med Hypotheses 74(5):802–806CrossRefPubMedGoogle Scholar
  26. 26.
    Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK (1982) Diagnosis of coliform infection in acutely dysuric women. N Engl J Med 307(8):463–468CrossRefPubMedGoogle Scholar
  27. 27.
    Stark RP, Maki DG (1984) Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant? N Engl J Med 311(9):560–564CrossRefPubMedGoogle Scholar
  28. 28.
    Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH (2011) Prevalence of “low-count” bacteriuria in female urinary incontinence versus continent female controls: a cross-sectional study. Int Urogynecol J 22(10):1267–1272CrossRefPubMedGoogle Scholar

Copyright information

© The International Urogynecological Association 2015

Authors and Affiliations

  • Krystal J. Thomas-White
    • 1
  • Evann E. Hilt
    • 1
  • Cynthia Fok
    • 2
  • Meghan M. Pearce
    • 1
  • Elizabeth R. Mueller
    • 3
    • 10
  • Stephanie Kliethermes
    • 4
  • Kristin Jacobs
    • 5
  • Michael J. Zilliox
    • 6
  • Cynthia Brincat
    • 3
    • 10
  • Travis K. Price
    • 1
  • Gina Kuffel
    • 7
  • Paul Schreckenberger
    • 8
  • Xiaowu Gai
    • 9
  • Linda Brubaker
    • 3
    • 10
  • Alan J. Wolfe
    • 1
  1. 1.Departments of Microbiology and Immunology, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  2. 2.Department of UrologyUniversity of MinnesotaMinneapolisUSA
  3. 3.Departments of Obstetrics & Gynecology and Urology, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  4. 4.Departments of Medicine and Public Health Sciences, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  5. 5.Department of Obstetrics & Gynecology, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  6. 6.Department of Public Health Sciences, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  7. 7.Center for Biomedical Informatics, Loyola Genomics FacilityLoyola University ChicagoMaywoodUSA
  8. 8.Department of Pathology, Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  9. 9.Department of Ophthalmology, Harvard Medical SchoolMassachusetts Eye and Ear InfirmaryBostonUSA
  10. 10.Departments of Obstetrics and Gynecology and Urology, Division of Female Pelvic Medicine and Reconstructive Surgery, Stritch School of MedicineLoyola University ChicagoMaywoodUSA

Personalised recommendations